Evaxion’s Personalized Cancer Vaccine EVX-01 Shows Durable Responses in Advanced Melanoma — Evaxion A/S

Event summary

Evaxion will present three-year clinical efficacy data for its personalized cancer vaccine EVX-01 at the ESMO Congress 2026.
The phase 2 trial extension evaluated EVX-01 as a stand-alone therapy in advanced melanoma patients, following initial combination treatment with KEYTRUDA®.
Two-year data showed a 75% Objective Response Rate (ORR) and 92% durable responses at two years with no relapses observed.

The big picture

Evaxion’s presentation of long-term data for EVX-01 comes as the personalized cancer vaccine field gains momentum, with AI-driven platforms accelerating target discovery and drug development. The durability of responses observed in advanced melanoma patients positions Evaxion to compete alongside established players like Merck & Co., particularly if stand-alone efficacy is confirmed.

What we're watching

Clinical Efficacy: Whether the three-year data confirms enhanced treatment effects and durability of EVX-01’s immune response as a stand-alone therapy.
Market Positioning: How Evaxion leverages these results to attract potential business partners in the competitive personalized cancer vaccine field.
Regulatory Pathway: The pace at which Evaxion advances EVX-01 into pivotal late-stage trials following these promising phase 2 outcomes.